Q-omics provides the consensus-scored CUL4A profile across patient tissues and cancer cell-line models. CUL4A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CUL4A is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CUL4A protein abundance shows 20,852 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where CUL4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CUL4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CUL4A survival associations across molecular data types. CUL4A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CUL4A RNA expression–survival associations across cancer types. High CUL4A expression shows unfavorable associations in ACC, CESC, HNSC, LIHC and LGG, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CUL4A RNA expression.
This table summarizes CUL4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CUL4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CUL4A shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, STAD, LIHC and BRCA. The COAD box plot shows higher CUL4A RNA expression in tumor versus normal tissue (log2 FC = +1.020, t-test p < 0.001).
This table shows molecular features associated with CUL4A in patient tissues and cancer cell lines. In patient samples, CUL4A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CUL4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
